A2A Pharmaceuticals is a New York-based company that utilizes proprietary computational systems, including artificial intelligence, to expedite the development of innovative drug alternatives for life-threatening diseases such as cancer, bacterial infections, and muscular dystrophy.
The company has achieved significant milestones, including partnerships with DAEWOONG Pharmaceutical and Insilico Medicine, as well as raising $55 million for its BIOMEA FUSION spin-off company focused on MLL-Menin and securing seed funding through SOSV and incubation at IndieBio.
Generated from the website